Therapeutic Strategies in Huntington's Disease
Open Access
- 1 January 2006
- journal article
- Published by XMLink in Journal of Clinical Neurology
- Vol. 2 (4) , 213-224
Abstract
Kanazawa I. J Clin Neurol. 2006 Dec;2(4):213-224. http://dx.doi.org/10.3988/jcn.2006.2.4.213Keywords
This publication has 85 references indexed in Scilit:
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006
- rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouseBiochemical and Biophysical Research Communications, 2006
- Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic miceMolecular Therapy, 2005
- RNA interferenceNature, 2002
- Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamineBiochemical and Biophysical Research Communications, 2002
- Loss of normal huntingtin function: new developments in Huntington's disease researchTrends in Neurosciences, 2001
- Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in YeastJournal of Biological Chemistry, 1998
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- A controlled clinical trial of baclofen as protective therapy in early huntington's diseaseAnnals of Neurology, 1989
- Huntington'S disease: Treatment with muscimol, A GABA‐mimetic drugAnnals of Neurology, 1978